期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

并存疾病对氯吡格雷抗血小板治疗的影响 被引量：7

原文传递
导出
摘要 氯吡格雷用于预防冠心病患者经皮冠状动脉介入术（PCI）后的血栓事件，但仍有4％～30％的患者在常规剂量治疗中达不到预期效果。研究者把常规治疗剂量氯吡格雷在血小板功能试验中未能达到预期的抗血小板作用，仍有临床事件的发生，称为氯吡格雷低反应或无反应，即氯吡格雷抵抗。
作者 苏嘉 杜为平 陈晓敏
机构地区 宁波大学医学院附属宁波市第一医院心内科
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2013年第7期626-628,共3页 Chinese Journal of Cardiology
关键词 氯吡格雷抵抗 抗血小板治疗 并存疾病 经皮冠状动脉介入术 血小板功能试验 冠心病患者 抗血小板作用 血栓事件
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献39

  • 1Gremmel T, Panzer S. Clinical, genetic and confounding factorsdetermine the dynamics of the in vitro response/non response toclopidogrel. Thromb and haemost,2011,106:211-218.
  • 2Park KW, Park JJ, Jeon KH, et al. Clinical predictors of highposttreatment platelet reactivity to clopidogrel in Koreans.Cardiovasc Ther, 2012, 30:5-11.
  • 3Gurbel PA,Bliden KP,Hiatt BL,et al. Clopidogrel for coronarystenting: response variability, drug resistance, and the effect ofpretreatment platelet reactivity. Circulation, 2003,107 : 2908-2913.
  • 4Cuisset T, Frere C, Quilici J, et al. Role of the T744Cpolymorphism of the P2Y12 gene on platelet response to a 600-mgloading dose of clopidogrel in 597 patients with non-ST-segmentelevation acute coronary syndrome. Thromb Res, 2007,120 :893-899.
  • 5Malek LA,Spiewak M,Filipiak KJ,et al. Persistent plateletactivation is related to very early cardiovascular events in patientswith acute coronary syndromes. Kardiol Pol, 2007 , 65:40*45.
  • 6Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrelloading doses according to vasodilator-stimulated phosphoproteinphosphorylation index decrease rate of major adverse cardiovascularevents in patients with clopidogrel resistance : a multicenterrandomized prospective study. J Am Coll Cardiol, 2008, 51:1404-1411.
  • 7Farhan S, Hochtl T, Kautzky-Willer A, et al. Antithrombotictherapy in patients with coronary artery disease and with type 2diabetes mellitus. Wien Med Wochenschr, 2010,160:30-38.
  • 8Harding SA, Sarma J, Din JN, el al. Clopidogrel reduces platelet-leucofyte aggregation,monocyte activation and RANTES secretionin type 2 diabetes mellitus. Heart, 2006, 92 ; 1335-1337.
  • 9Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochromeP450 2C19 loss-of-function polymorphism and of majordemographic* characteristics on residual platelet function afterloading and maintenance treatment with clopidogrel in patientsundergoing elective coronary stent placement. J Am Coll Cardiol,2010, 55:2427-2434.
  • 10Erlinge D, Varenhorst C, Braun OO, et al. Patients with poorresponsiveness to thienopyridine treatment or with diabetes havelower levels of circulating active metabolite, but their plateletsrespond normally to active metabolite added ex vivo. J Am CollCardiol,2008, 52 : 1968-1977.

二级参考文献12

  • 1de la Torre-Hernandez JM, Alfonso F, Hernaindez F, et al. Drug- eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA. J Am Coil Cardiol, 2008, 51 : 986-990.
  • 2Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol, 2005,45:1157-1164.
  • 3Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stentiug are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12- month follow-up. Circulation, 2009, 119:237-242.
  • 4Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J, 2008, 29:992-1000.
  • 5von Beckerath N, Pogatsa-Murray G, Wieczorek A, et al. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost, 2006, 95:910 -911.
  • 6Suh JW, Lee SP, Park KW, et al. Muhicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of eilostazol- based triple antiplatelet therapy on ischemic complication 'after drug-eluting stent implantation) trial. J Am Coil Cardiol, 2011, 57:280-289.
  • 7Price M J, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRA VITAS randomized trial. .lAMA, 2011, 305 : 1097-1105.
  • 8Berger JS, Bhatt DL, Cannon CP, et al. The relative efficacy and safety of elopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol, 2009, 54 : 1935-1945.
  • 9Dorsch MP, Lee JS, Lynch DR, et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother, 2007, 41: 737-741.
  • 10Ueno M, Ferreiro JL, Tomasello SD, et al. Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thromb Haemost, 2011, 105:730-732.

共引文献13

同被引文献56

  • 1韩雅玲,梁明,荆全民,王守力,马颖艳,栾波.52例冠状动脉支架内血栓形成患者的临床特点及介入治疗[J].中华心血管病杂志,2006,34(11):975-978. 被引量：34
  • 2Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxebeluting stents [J]. Circulation, 2006,113 (8) :1108-1113.
  • 3Kirtane AJ, Stone GW. How to minimize stent thrombosis [J]. Circulation, 2011, 124(11) 1283-1287.
  • 4Machecourt J Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetie patients the EVASTENT Matched- Cohort Registry[J]. J Am Coil Cardiol,2007,50(6) :501 508.
  • 5Nusca A,Patti G. Platelet function and inhibition in ischemic heart disease [J]. Curt Cardiol Rep,2012,14(4) : 457-467.
  • 6Lau WC,Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopideogrel to inhabit platelet aggregation: a new drug-drug interaction [J]. Circulation, 2003, 107 ( 1 ) : 32- 37.
  • 7Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and elopidogrel: result from the interaction study[J]. Arch Intern Med,2004,164(18) 2051-2057.
  • 8Sommer P, Armstrong EJ. Stent thrombosis current management and outcomes[J]. Curr Treat Options Cardiovasc Med, 2015,17 (3) : 365.
  • 9Tsoukas A,Andonakoudis H,Christakos S.Short-term exercise training effect after myocardial infarction on myocardial oxygen consumption indices[J].Arch Phys Med Rehabil,1995,76:262-265.
  • 10李森林,杜佩珊.氯吡格雷联合阿昔莫司对冠心病患者颈动脉的影响[C].//第七届华北长城心脏病学会议、河北省心血管病学2014年会暨第三届经前臂(桡/尺)动脉微创化冠脉介入治疗国际论坛论文集.2014:273-273.

引证文献7

二级引证文献54

中华心血管病杂志
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部